3,010 Shares of United Therapeutics Corporation $UTHR Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,010 shares of the biotechnology company’s stock, valued at approximately $1,631,000.

Several other institutional investors and hedge funds have also recently modified their holdings of UTHR. Profund Advisors LLC increased its position in shares of United Therapeutics by 51.7% in the third quarter. Profund Advisors LLC now owns 5,208 shares of the biotechnology company’s stock valued at $2,822,000 after buying an additional 1,776 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of United Therapeutics by 1.6% during the 3rd quarter. ProShare Advisors LLC now owns 3,117 shares of the biotechnology company’s stock valued at $1,689,000 after buying an additional 50 shares in the last quarter. MGO One Seven LLC lifted its position in shares of United Therapeutics by 4.5% during the 3rd quarter. MGO One Seven LLC now owns 953 shares of the biotechnology company’s stock valued at $516,000 after buying an additional 41 shares in the last quarter. State of Wyoming acquired a new position in United Therapeutics during the third quarter worth $141,000. Finally, China Universal Asset Management Co. Ltd. raised its position in United Therapeutics by 19.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,076 shares of the biotechnology company’s stock worth $4,376,000 after acquiring an additional 1,321 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $598.67, for a total transaction of $4,968,961.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $27,043,121.24. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine Rothblatt sold 1,960 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $597.76, for a total transaction of $1,171,609.60. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $193,939,047.68. This represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 411,028 shares of company stock valued at $218,476,169. Corporate insiders own 8.60% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets and kept bullish ratings. BTIG maintained a Buy rating with a $768 target, citing Tyvaso momentum; Royal Bank of Canada raised its target to $725 and TD Cowen to $700. BTIG analyst outlook
• Positive Sentiment: Third-quarter revenue increased 4.1% year over year to $832.5 million, exceeding analyst expectations of about $781 million. The company also has a $2 billion share-repurchase authorization, which could support demand for its shares.
• Negative Sentiment: Quarterly EPS of $5.71 missed the $6.01 consensus and was below $7.16 a year earlier. The earnings shortfall and year-over-year decline in EPS could offset the revenue beat.
• Negative Sentiment: CEO Martine Rothblatt reported multiple share sales, while EVP Paul Mahon sold 8,300 shares. Insider sales can unsettle investors, although both executives retained substantial holdings after their transactions. CEO sale filing EVP sale filing

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a report on Thursday. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research report on Wednesday, October 28th. UBS Group set a $725.00 price target on shares of United Therapeutics in a research report on Monday, October 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a research note on Monday, October 26th. Finally, Morgan Stanley lifted their price objective on United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $676.40.

United Therapeutics Trading Down 0.7%

Shares of UTHR opened at $562.02 on Friday. United Therapeutics Corporation has a 12-month low of $444.04 and a 12-month high of $614.23. The firm has a 50-day moving average price of $533.99 and a 200 day moving average price of $533.42. The firm has a market capitalization of $23.94 billion, a P/E ratio of 21.21, a P/E/G ratio of 3.59 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. During the same quarter in the previous year, the business posted $7.16 earnings per share. United Therapeutics’s revenue for the quarter was up 4.1% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 24.77 earnings per share for the current fiscal year.

United Therapeutics declared that its Board of Directors has approved a stock buyback plan on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 8.3% of its stock through open market purchases. Share repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

United Therapeutics Company Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.